REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION REQUEST FORM

☐ In Network		☐ Out of Network			
MEMBER NAME:		DOB:		GENDER:	
HEALTH PLAN:		POLICY #:			
Date and Time	of Request:				
Treating Clinicia	an/Facility:				
If the treating c	linician is not making this request, has the treating clinicia	an been notifie	d? ☐ Yes ☐ No		
Phone #:		NPI/TIN#:			
Servicing Clinic	ian/Facility:				
Phone #:		NPI/TIN#:			
	INITIAL T	REATMENT			
1. Has a confirmed diagnosis of severe major depressive disorder (MDD) single or recurrent episode					
☐ F32.2	Major Depressive Disorder, Single Episode, Severe (Without Psychotic Features)				
☐ F33.3	Major Depressive Disorder, Recurrent Episode, Severe (Without Psychotic Features)				
Pre-treatment ra	ating scale: GDS, PHQ-9, BDI, HAM-D	, MADRS	, QIDS, or IDS-S	R	
AND					
2. One or more of the following:					
Resistance to treatment with psychopharmacologic agents as evidenced by a lack of a clinically significant response to four adequate trials of at least six weeks duration of psychopharmacologic agents in the current depressive episode from at least two different agent classes as documented by standardized rating scales that reliably measure depressive symptoms (GDS, PHQ-9, BDI, HAM-D, MADRS, QIDS, or IDS-SR); or Inability to tolerate psychopharmacologic agents as evidenced by four trials of psychopharmacologic agents from at least two different agent classes (at least one of which is in the antidepressant class), with distinct side effects; or History of response to rTMS in a previous depressive episode; or Currently receiving electroconvulsive therapy (ECT) Currently considering ECT; rTMS may be considered as a less invasive treatment option *Note for reference: Remission is typically defined by the following measurement scores: Beck Depression Scale (BDI) score of <9, Hamilton Depression Rating Scale (HAM-D) score of <8 on the HAM-D-17 and <11 on the HAM-D-24, Montgomery-Asberg Depression Rating Scale (MADRS) score of < 10, Patient Health Questionnaire (PHQ-9) score of < 5					
AND					
☐ 3. A trial of an <i>evidence-based psychotherapy</i> known to be effective in the treatment of MDD of an adequate frequency and duration without significant improvement in depressive symptoms as documented by standardized rating scales that reliably measure depressive symptoms (GDS, PHQ-9, BDI, HAM-D, MADRS, QIDS or IDS-SR).					
AND					
4. An order written by a psychiatrist (MD or DO) who has examined the patient and reviewed the record. The physician will have experience in administering TMS therapy. The treatment shall be given under direct supervision of this physician.					

Potential Contraindications (please select all applicable contraindications the patient has from the list below): Seizure disorder or any history of seizures (except those induced by ECT or isolated febrile seizures in infancy without subsequent treatment or recurrence)					
 Presence of acute or chronic psychotic symptoms or disorders in the current depressive episode Neurological conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, history of repetitive or severe head trauma, or primary or secondary tumors in the central nervous system Presence of an implanted magnetic-sensitive medical device located less than or equal to 30 cm from the TMS magnetic coil or other implanted 					
	cluding but not limited to a cochlear implant, implanted cardiac defibrillator (ICD), pacemaker, vagus nerve stimulation (VNS), or not coils, staples, or stents.				
Note: Dental amalgam fillings are not affected by the magnetic field and are acceptable for use with TMS.					
Prior failed trial of an adequate course of treatment with ECT or vagus nerve stimulation (VNS) for Major Depressive Disorder					
The patient is curr	ently: pregnant or nursing				
☐ The patient ha	s a current suicide plan or recent suicide attempt				
Eating Disorder	rder, including Schizoaffective Disorder				
History of (check t Substance Abu Obsessive Com Post-Traumatic	ise ipulsive Disorder				
	RETREATMENT				
☐ 1. Patient met	the guidelines for initial treatment AND meets guidelines currently.				
AND					
🗌 2. Subsequent	tly developed relapse of depressive symptoms				
AND					
☐ 3. Responded to prior treatments as evidenced by a greater than 50% improvement in standard rating scale measurements for depressive symptoms (e.g., GDS, PHQ-9, BDI, HAM-D, MADRS, QIDS or IDS-SR scores).					
Post-treatment rat	ing scale: GDS, PHQ-9, BDI, HAM-D, MADRS, QIDS, or IDS-SR				
Dates of initial trea	atment, if known:				
	TREATMENT TYPE(S) REQUESTED				
FDA-approved TI	MS device to be used for the following treatment:				
90867	THERAPEUTIC REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (TMS) TREATMENT — INITIAL, INCLUDING CORTICAL MAPPING, MOTOR THRESHOLD DETERMINATION, AND DELIVERY AND MANAGEMENT				
90868	THERAPEUTIC REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (TMS) TREATMENT — SUBSEQUENT DELIVERY AND MANAGEMENT, PER SESSION				
90869	THERAPEUTIC REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (TMS) TREATMENT — SUBSEQUENT MOTOR THRESHOLD REDETERMINATION WITH DELIVERY AND MANAGEMENT				